MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Income Overview
Net Income
-$215,733K
EPS
-$0.28
Unit: Thousand (K) dollars
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Income Statement
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Research and development
-
-
147,292
131,096
Reclassification of unrealized loss on short-term investments to other expense, net
-
0
0*
0
Acquired in-process research and development
-
-
0
0
Interest expense
-
0
0
0
Research and development
157,733
-
-
-
General and administrative
62,763
62,594
77,633
103,115
Total operating expenses
220,496
195,212
224,925
234,211
Other income, net
4,796
5,788
5,753
2,418
Net loss
-215,700
-189,424
-219,172
-231,793
Reclassification of cumulative currency translation gain to other income, net
-
-
0*
-
Foreign currency translation adjustments
34
84
-36
43
Unrealized loss on short-term investments
-67
-176
205
0
Comprehensive loss
-215,733
-189,516
-219,003
-231,750
Basic EPS
-0.28
-0.24
-0.286
-0.31
Diluted EPS
-0.28
-0.24
-0.286
-0.31
Basic Average Shares
778,184,568
775,458,141
766,702,133
743,415,917
Diluted Average Shares
778,184,568
775,458,141
766,702,133
743,415,917
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Income Statement
Comprehensive loss
-$215,733K
(61.88%↑ Y/Y)
Foreign currency
translation adjustments
$34K
(117.99%↑ Y/Y)
Net loss
-$215,700K
(61.87%↑ Y/Y)
Unrealized loss on
short-term investments
-$67K
Other income, net
$4,796K
(75.74%↑ Y/Y)
Total operating
expenses
$220,496K
(-61.21%↓ Y/Y)
Research and development
$157,733K
(-24.17%↓ Y/Y)
General and
administrative
$62,763K
(-82.59%↓ Y/Y)
Buy us a coffee
summitplc-logo_05fd32df-svg
Summit Therapeutics Inc. (SMMT)
summitplc-logo_05fd32df-svg
Summit Therapeutics Inc. (SMMT)